Smits et al report a retrospective cohort study which is one of the first to shed light on how the BMI of women diagnosed with endometrial cancer affects the toxicity of radiotherapy they receive and hence survivor quality of life.
Smits A et al. Int J Clin Oncol 2017; 22: 945. doi:10.1007/s10147-017-1147-5
The authors find that resistance exercise is a potent approach in counteracting increase of body fat as well as loss of muscle mass, muscle strength, and physical performance in patients suffering from prostate cancer.
Keilani M, Hasenoehrl T, Baumann L et al. Support Care Cancer 2017;25:2953–2968. doi:10.1007/s00520-017-3771-z
This study finds suboptimal hepatocellular carcinoma (HCC) surveillance rates in patients with cirrhosis: Only 49% received surveillance within 6 months and 78% received HCC surveillance within 1 year.
Tavakoli H, Robinson A, Liu B et al. Dig Dis Sci 2017;62:2174–2181. doi:10.1007/s10620-017-4595-x
This article catalogs the range of issues encountered by long-term survivors of glioblastoma and provides greater insight into the symptom burden and care needs of this small, yet important population.
Gately L et al. J Cancer Surviv 2017; 11: 447–452. doi:10.1007/s11764-017-0602-7
The authors investigated whether the use of a web-based system, involving self-screening, patient education, and self-referral to professional healthcare, is feasible in patients with neuroendocrine tumors.
Bouma G et al. Support Care Cancer 2017; 25: 2075–2083. doi:10.1007/s00520-017-3598-7
Vinik et al. examined the health-related quality of life (HRQoL) of sunitinib-treated patients with pancreatic neuroendocrine tumors and found that survival increased without adversely affecting HRQoL.
Vinik A et al. Targ Oncol 2016; 11: 815–824. doi:10.1007/s11523-016-0462-5
This chapter provides an overview of the early development and clinical studies of the serotonin (5-hydroxytryptamine-3) receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting.
Chen R, Deng K, Raftopoulos H. In: Management of Chemotherapy-Induced Nausea and Vomiting. Edited by: Navari R. Springer International Publishing Switzerland 2016. doi: 10.1007/978-3-319-27016-6_3
A phase III study was designed to evaluate the efficacy of oral netupitant/palonosetron (NEPA) compared with palonosetron in prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple chemotherapy cycles. Reported here are the results of a multiple cycle extension for the prevention of CINV in patients receiving anthracycline-cyclophosphamide chemotherapy.
Aapro M et al. Support Care Cancer 2017; 25: 1127–1135. doi: 10.1007/s00520-016-3502-x